MRNA · Analysis updated Nov 6, 2026, 6:04 PM ET

Why is Moderna, Inc. (MRNA) stock moving?

Moderna delivered a standout Q3 2026 financial report on Nov 6, posting total revenue of $1.31B (up 29% year over year) against consensus expectations of roughly $885M. The company achieved GAAP net income of $162M ($0.38 per share), reversing a $200M loss in Q3 2025 and topping forecasts of a $1.25 per share loss. Supported by strong international vaccine deliveries under multi-year government pacts, management lifted its FY2026 revenue growth outlook to 15%-25% (up from <=10%), reduced full-year R&D expense guidance to $2.7B, and raised expected year-end cash to $8.1B-$8.3B. Operationally, regulatory progress continues with Health Canada authorizing both mFLUSIVA and combination vaccine mCOFLU, while preparation for intismeran autogene oncology regulatory submissions progresses. In trading following a volatile swing down to $241.46 on Nov 5, shares rallied strongly into the $255-$267 zone post-earnings. Valuation remains elevated following a 700%+ year-to-date run, but operational turnaround and pipeline execution provide solid fundamental backing.

News behind the analysis

Moderna Reports Q3 2026 Earnings: Returns to Profitability and Lifts Guidance
Accesswire · Nov 6, 2026
Moderna posted Q3 revenue of $1.31B, up 29% year over year and topping consensus of $885.1M, generating net income of $162M ($0.38 per share) versus an expected loss.
Moderna Raises 2026 Revenue Growth Forecast to 15%-25%
Quartz · Nov 6, 2026
Management raised full-year 2026 revenue growth guidance to 15%-25% from up to 10% and projected year-end cash balances of $8.1B to $8.3B.
Health Canada Authorizes Moderna's mFLUSIVA and Combination Vaccine mCOFLU
BioSpace · Nov 6, 2026
Health Canada granted regulatory authorization for seasonal influenza vaccine mFLUSIVA and combination vaccine mCOFLU for adults aged 50 and older.
Moderna Q3 2026 Earnings Call: Revenue Up 29%, R&D Budget Trimmed
TradingKey · Nov 6, 2026
Moderna cut its 2026 R&D budget by $200M to $2.7B and lowered full-year cash operating costs to $3.8B amid clinical and manufacturing optimization.
Moderna Surges on Surprise Profit and Cancer Vaccine Advancements
The Motley Fool · Nov 6, 2026
Shares rallied toward $263-$267 following surprise profitability and continued momentum heading into upcoming regulatory filings for intismeran autogene.

In the Daily Standout

November 6, 2026: on the shortlist +8.19%

This analysis is for informational purposes only and does not constitute financial, investment, or trading advice. Biopharmaceutical equities are subject to high volatility and regulatory risks.